LONDON, Sept. 12,
2023 /PRNewswire/ -- Virax Biolabs Group Limited
("Virax" or the "Company") (Nasdaq: VRAX), an innovative
diagnostics company focused on the detection of immune responses
and diagnosis of viral diseases, announced today the launch of
an early access program for the research-use-only ("RUO") of its
proprietary SARS-Cov-2 ViraxImmune T-cell-based test. The company
will host a webinar on September 20,
2023 at 10 AM EST.
The early access program offers select research groups an
opportunity to be at the forefront of immune assessment
advancements. The RUO form of Virax's T-cell-based test is designed
to assess the activation of memory T-cells specific to the
SARS-Cov-2 by combining an ELISpot assay with a peptide pool
covering specific protein parts of the virus. The test requires the
isolation of peripheral blood mononuclear cells ("PBMCs") from
blood samples that are then seeded onto the Company's pre-coated
ELISpot plate. The cytokines secreted by the cells upon stimulation
with the peptide pool are immediately captured by the antibodies
bound to the plate and detected through a series of reactions with
antibodies and enzyme-substrate interactions, resulting in visible
spots. Each spot represents a single cytokine-secreting cell,
allowing for high-resolution analysis of immune responses at the
cellular level. This test provides a quantitative assessment of
immune response, which will help to develop a deeper understanding
of an individual's immune profile. The Company's tests are
compatible with a wide range of ELISpot readers, ensuring ease of
use without requiring additional costly laboratory equipment.
"We are thrilled to launch this early access program for the RUO
of our proprietary ViraxImmune T-cell based test," said Mr.
James Foster, Chairman of the Board
and Chief Executive Officer of Virax Biolabs. "We look forward
to working with early adopters who also share the vision to be at
the frontier of cutting-edge diagnostics and bringing value to
human immune health."
"We are excited to get our proprietary T-cell-based tests in the
hands of researchers as demand is growing for T-cell tests due to
its advantages when compared to antigen and antibody-based tests in
the context of determining long-term immunity to viral threats,"
commented Dr. Tomasz George, Chief
Scientific Officer of Virax Biolabs. "Although this initial
iteration of our test targets specifically Sars-Cov-2, we believe
that our tests are adaptable to a broad range of immunological
threats in different settings, from personal use to utilization by
governments and the pharmaceutical industry."
The Company will host a webinar for interested research
institutions and the investment community on September 20, 2023 at 10
AM ET. Participants may register their interest for the
event to receive updates and instructions to join the call by
visiting
https://www.viraxbiolabs.com/viraximmune-early-access-programme.
About Virax Biolabs Group Limited.
Founded in 2013, Virax Biolabs Group Limited is an innovative
biotech company focused on the detection of immune responses to and
diagnosis of viral diseases. In addition to distributing an array
of in-vitro diagnostic test kits, Virax Biolabs Group Limited is
currently developing a proprietary T-Cell Test technology with the
intention of providing an immunology profiling platform that
assesses each individual's immune risk profile against major global
viral threats. T-Cell testing can be particularly effective in the
diagnosis of and therapeutics to combat COVID-19 as well as other
threats including Monkeypox, Hepatitis B, Malaria, Herpes and Human
Papillomavirus.
For more information, please
visit www.viraxbiolabs.com.
Caution Concerning Forward Looking Statements:
This press release contains forward-looking statements. In
addition, from time to time, we or our representatives may make
forward-looking statements orally or in writing. We base these
forward-looking statements on our expectations and projections
about future events, which we derive from the information currently
available to us. Such forward-looking statements relate to future
events or our future performance, including: our financial
performance and projections; our growth in revenue and earnings;
and our business prospects and opportunities. You can identify
forward-looking statements by those that are not historical in
nature, particularly those that use terminology such as "may,"
"should," "expects," "anticipates," "contemplates," "estimates,"
"believes," "plans," "projected," "predicts," "potential," or
"hopes" or the negative of these or similar terms. In evaluating
these forward-looking statements, you should consider various
factors, including: our ability to change the direction of the
Company; our ability to keep pace with new technology and changing
market needs; and the competitive environment of our business.
These and other factors may cause our actual results to differ
materially from any forward-looking statement. Forward-looking
statements are only predictions. The forward-looking events
discussed in this press release and other statements made from time
to time by us or our representatives, may not occur, and actual
events and results may differ materially and are subject to risks,
uncertainties, and assumptions about us. These forward-looking
statements are based on information currently available to Virax
and its current plans or expectations and are subject to a number
of known and unknown uncertainties, risks and other important
factors that may cause our actual results, performance or
achievements to be materially different from any future results,
performance or achievements expressed or implied by the
forward-looking statements. These and other important factors are
described in detail in the "Risk Factors" section of Virax's Annual
Report on Form 20-F for the year ended March 31, 2023.
Although we believe the expectations reflected in such
forward-looking statements are reasonable, we can give no assurance
that such expectations will prove to be correct. We are not
obligated to publicly update or revise any forward-looking
statement, whether as a result of uncertainties and assumptions,
the forward-looking events discussed in this press release and
other statements made from time to time by us or our
representatives might not occur.
Company Contact:
Virax Biolabs Group Limited
Phone: +44 020 7788 7414
Email: info@viraxbiolabs.com
Media and Investor Contact:
Nic Johnson and Adanna Alexander
Russo Partners, LLC
(303) 482-6405
nic.johnson@russopartnersllc.com
adanna.alexander@russopartnersllc.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/virax-biolabs-group-announces-early-access-program-launch-of-research-use-only-viraximmune-product-and-hosts-webinar-301924476.html
SOURCE Virax Biolabs